{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:06:38Z","timestamp":1790089598348,"version":"4.0.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICI) have become standard of care for renal cell carcinoma (RCC) in the adjuvant, first-line and pre-treated settings. However, treatment patterns and outcomes of patients with RCC that progresses following ICI treatment are not well characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review of electronic health records from a US community oncology network included patients with metastatic clear cell RCC (mccRCC) that progressed after an initial ICI-containing regimen and received subsequent systemic therapy (index) between 01\/01\/2018 and 01\/31\/2023. Patient characteristics and treatment patterns were described. Real-world progression-free survival (rwPFS) and overall survival (OS) were analyzed using Kaplan-Meier method by line of therapy (LOT) of the first ICI-containing regimen and index regimen class.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 299 patients were included (median [IQR] age 68 [60-75] years, 73% male, 85% white, 87% intermediate or poor IMDC risk, median follow-up 11.3\u2009months) with the first ICI-containing regimen initiated in the adjuvant (n\u2009=\u20095, 2%), first-line (n\u2009=\u2009203, 68%) or second-line (n\u2009=\u200991, 30%) settings. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) monotherapy was the most common index (post-IO) regimen class (62% any VEGFR-TKI, 46% cabozantinib). Median (95% CI) rwPFS and OS were 6.0 (5.4, 6.8) and 14.3 (12.1, 16.4) months, respectively. No differences were observed in rwPFS and OS by LOT of the first ICI-containing regimen (P\u2009=\u20090.763, P\u2009=\u20090.885, respectively) or index regimen class (P\u2009=\u20090.721, P\u2009=\u20090.747, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In real-world patients with mccRCC that progressed to the post-ICI setting, VEGFR-TKI monotherapies were the most common post-ICI regimens and differences in clinical outcomes were not observed by LOT of the first ICI-containing regimen or index regimen class. There is high unmet need for novel therapies in the post-ICI setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag326","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:05:06Z","timestamp":1789473906000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment patterns and outcomes in metastatic clear cell renal cell carcinoma following immune checkpoint inhibitor progression (2018-2023)"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5752-6212","authenticated-orcid":false,"given":"Neil J","family":"Shah","sequence":"first","affiliation":[{"name":"Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY 10021,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8403-0386","authenticated-orcid":false,"given":"Rahul","family":"Ravilla","sequence":"additional","affiliation":[{"name":"US Oncology Network\/New York Oncology Hematology , Albany, NY 12206,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4488-0604","authenticated-orcid":false,"given":"Andrew J","family":"Osterland","sequence":"additional","affiliation":[{"name":"Ontada , Boston, MA 02110,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8238-1615","authenticated-orcid":false,"given":"Karen","family":"Todoroff","sequence":"additional","affiliation":[{"name":"Ontada , Boston, MA 02110,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. , Rahway, NJ 07065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Rane","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. , Rahway, NJ 07065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Saal","sequence":"additional","affiliation":[{"name":"Formerly of Eisai Inc. , Nutley, NJ 07110,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5624-8799","authenticated-orcid":false,"given":"Paul R","family":"Conkling","sequence":"additional","affiliation":[{"name":"Ontada , Boston, MA 02110,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Wang","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. , Rahway, NJ 07065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-2327","authenticated-orcid":false,"given":"Robert J","family":"Motzer","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College , New York, NY 10021,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"2026092210523715300_oyag326-B1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026092210523715300_oyag326-B2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"2026092210523715300_oyag326-B3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"2026092210523715300_oyag326-B4","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026092210523715300_oyag326-B5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/oncolo\/oyab056","article-title":"First-line treatments for metastatic clear cell renal cell carcinoma: an ever-enlarging landscape","volume":"27","author":"Gulati","year":"2022","journal-title":"Oncologist"},{"key":"2026092210523715300_oyag326-B6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.euros.2022.12.015","article-title":"Real-world treatment patterns and clinical outcomes for metastatic renal cell carcinoma in the current treatment era","volume":"49","author":"Shah","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"2026092210523715300_oyag326-B7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.eururo.2024.04.025","article-title":"Cabozantinib plus nivolumab in patients with non\u2013clear cell renal cell carcinoma: updated results from a phase 2 trial","volume":"86","author":"Fitzgerald","year":"2024","journal-title":"Eur Urol"},{"key":"2026092210523715300_oyag326-B8","doi-asserted-by":"publisher","first-page":"459.e1","DOI":"10.1016\/j.urolonc.2023.08.009","article-title":"Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab\u202f+\u202faxitinib vs. ipilimumab\u202f+\u202fnivolumab","volume":"41","author":"Shah","year":"2023","journal-title":"Urol Oncol"},{"key":"2026092210523715300_oyag326-B9","doi-asserted-by":"publisher","first-page":"e2422674","DOI":"10.1001\/jamanetworkopen.2024.22674","article-title":"Health care resource use for modern first-line treatments in metastatic renal cell carcinoma","volume":"7","author":"Shah","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026092210523715300_oyag326-B10","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/s1470-2045(23)00276-0","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026092210523715300_oyag326-B11","doi-asserted-by":"publisher","first-page":"102881","DOI":"10.1016\/j.ctrv.2025.102881","article-title":"Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma","volume":"133","author":"Santoni","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"2026092210523715300_oyag326-B12","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1200\/jco.19.03315","article-title":"Salvage ipilimumab and nivolumab in patients with metastatic renal cell carcinoma after prior immune checkpoint inhibitors","volume":"38","author":"Gul","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026092210523715300_oyag326-B13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.eururo.2022.10.017","article-title":"Progression-free survival after second line of therapy for metastatic clear cell renal cell carcinoma in patients treated with first-line immunotherapy combinations","volume":"83","author":"Fitzgerald","year":"2023","journal-title":"Eur Urol"},{"key":"2026092210523715300_oyag326-B14","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1158\/1078-0432.Ccr-24-1199","article-title":"FDA approval summary: belzutifan for patients with advanced renal cell carcinoma","volume":"30","author":"Fallah","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026092210523715300_oyag326-B15","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1200\/jco.23.02082","article-title":"Bempegaldesleukin plus nivolumab versus sunitinib or cabozantinib in previously untreated advanced clear cell renal cell carcinoma: a phase III randomized study (PIVOT-09)","volume":"42","author":"Tannir","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026092210523715300_oyag326-B16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2023.41.6_suppl.666","article-title":"A phase 1b\/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC)","volume":"41","author":"Shah","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026092210523715300_oyag326-B17","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.euo.2023.10.017","article-title":"A phase 2 trial of talazoparib and avelumab in genomically defined metastatic kidney cancer","volume":"7","author":"Kotecha","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2026092210523715300_oyag326-B18","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1093\/oncolo\/oyad216.015","article-title":"The identification of a novel orally available ferroptosis inducer for the treatment of clear cell renal carcinoma","volume":"28","author":"Koh","year":"2023","journal-title":"Oncologist"},{"key":"2026092210523715300_oyag326-B19","doi-asserted-by":"publisher","first-page":"TPS4600","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4600","article-title":"A phase 1b study (STELLAR-002) of XL092 administered in combination with nivolumab (NIVO) with or without ipilimumab (IPI) or bempegaldesleukin (BEMPEG) in patients (pts) with advanced solid tumors","volume":"40","author":"Choueiri","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026092210523715300_oyag326-B20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/s1470-2045(21)00241-2","article-title":"Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111\/KEYNOTE-146): a phase 1b\/2 study","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026092210523715300_oyag326-B21","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1200\/jco.21.00939","article-title":"Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study","volume":"39","author":"Pal","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026092210523715300_oyag326-B22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.annonc.2020.09.021","article-title":"TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma","volume":"32","author":"Albiges","year":"2021","journal-title":"Ann Oncol"},{"key":"2026092210523715300_oyag326-B23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/s0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"2026092210523715300_oyag326-B24","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"key":"2026092210523715300_oyag326-B25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2217\/fon-2022-0802","article-title":"LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1\/PD-L1 therapy","volume":"19","author":"Motzer","year":"2023","journal-title":"Future Oncol"},{"key":"2026092210523715300_oyag326-B26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.annonc.2025.10.009","article-title":"A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)","volume":"37","author":"Hahn","year":"2026","journal-title":"Ann Oncol"},{"key":"2026092210523715300_oyag326-B27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(24)00649-1","article-title":"Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study","volume":"26","author":"Choueiri","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026092210523715300_oyag326-B28","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1200\/JCO.2025.43.16_suppl.4506","article-title":"Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma","volume":"43","author":"Choueiri","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026092210523715300_oyag326-B29","author":"The US Oncology Network"},{"key":"2026092210523715300_oyag326-B30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejca.2019.04.003","article-title":"Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors","volume":"114","author":"Shah","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026092210523715300_oyag326-B31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12894-020-00647-w","article-title":"Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations","volume":"20","author":"Ged","year":"2020","journal-title":"BMC Urol"},{"key":"2026092210523715300_oyag326-B32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1200\/JCO.2021.39.6_suppl.288","article-title":"Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma (mRCC) using real-world data","volume":"39","author":"Geynisman","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026092210523715300_oyag326-B33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.eururo.2024.07.016","article-title":"First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma: an international multicenter study","volume":"86","author":"El Zarif","year":"2024","journal-title":"Eur Urol"},{"key":"2026092210523715300_oyag326-B34","doi-asserted-by":"publisher","first-page":"106.e1","DOI":"10.1016\/j.clgc.2022.07.008","article-title":"CABOSEQ: the effectiveness of cabozantinib in patients with treatment refractory advanced renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)","volume":"21","author":"Navani","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"2026092210523715300_oyag326-B35","doi-asserted-by":"publisher","first-page":"LBA417","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA417","article-title":"Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti\u2013PD-(L)1 therapy: open-label phase 3 LITESPARK-011 study","volume":"44","author":"Motzer","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026092210523715300_oyag326-B36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005780","article-title":"FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy","volume":"10","author":"Choueiri","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026092210523715300_oyag326-B37","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1200\/JCO.2025.43.5_suppl.440","article-title":"KEYMAKER-U03 Substudy 03B: pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC)","volume":"43","author":"Albiges","year":"2025","journal-title":"Journal of Clinical Oncology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag326\/71089440\/oyag326.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag326\/71089440\/oyag326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag326\/71089440\/oyag326.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:52:43Z","timestamp":1790088763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag326\/8796067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag326","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,9]]},"article-number":"oyag326"}}